Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16483
Title: Capture and on-chip analysis of melanoma cells using tunable surface shear forces
Austin Authors: Tsao, Simon Chang-Hao;Vaidyanathan, Ramanathan;Dey, Shuvashis;Carrascosa, Laura G;Christophi, Christopher ;Cebon, Jonathan S ;Shiddiky, Muhammad JA;Behren, Andreas;Trau, Matt
Affiliation: Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Surgery - Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
Ludwig Institute for Cancer Research - Austin Health, Heidelberg, Victoria, Australia
Centre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia
School of Cancer Medicine- La Trobe University, Melbourne, Victoria, Australia
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia
Issue Date: Jan-2016
Publication information: Scientific Reports 2016; 6: 19709
Abstract: With new systemic therapies becoming available for metastatic melanoma such as BRAF and PD-1 inhibitors, there is an increasing demand for methods to assist with treatment selection and response monitoring. Quantification and characterisation of circulating melanoma cells (CMCs) has been regarded as an excellent non-invasive candidate but a sensitive and efficient tool to do these is lacking. Herein we demonstrate a microfluidic approach for melanoma cell capture and subsequent on-chip evaluation of BRAF mutation status. Our approach utilizes a recently discovered alternating current electrohydrodynamic (AC-EHD)-induced surface shear forces, referred to as nanoshearing. A key feature of nanoshearing is the ability to agitate fluid to encourage contact with surface-bound antibody for the cell capture whilst removing nonspecific cells from the surface. By adjusting the AC-EHD force to match the binding affinity of antibodies against the melanoma-associated chondroitin sulphate proteoglycan (MCSP), a commonly expressed melanoma antigen, this platform achieved an average recovery of 84.7% from biological samples. Subsequent staining with anti-BRAF(V600E) specific antibody enabled on-chip evaluation of BRAF(V600E) mutation status in melanoma cells. We believe that the ability of nanoshearing-based capture to enumerate melanoma cells and subsequent on-chip characterisation has the potential as a rapid screening tool while making treatment decisions.
URI: https://ahro.austin.org.au/austinjspui/handle/1/16483
DOI: 10.1038/srep19709
Journal: Scientific Reports
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26815318
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Nov 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.